You are here: Home: PCU 1 | 2006: Mark S Soloway, MD: Select publications

SELECT PUBLICATIONS

Bartsch G et al; Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001;58(3):417-24. Abstract

Bolla M et al; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. Abstract

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

Denham JW et al; Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans- Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6(11):841-50. Abstract

Hanks GE et al; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Klotz L. Combined androgen blockade in prostate cancer: Meta-analyses and associated issues. BJU Int 2001;87(9):806-13. No abstract available

Kundu SD et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172(6 Pt 1):2227-31. Abstract

Lawton CA et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial: Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800-7. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8.Abstract

Pelzer AE et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: Observation and clinical implications from Tyrol screening project. Urology 2005;66(5):1029-33. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491-8. Abstract

Roach M 3RD et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47(3):617- 27. Abstract

Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 2005;23(32):8225-31. Abstract

Sofer M et al. Risk of positive margins and biochemical recurrence in relation to nervesparing radical prostatectomy. J Clin Oncol 2002;20(7):1853-8. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Tyrrell CJ et al; ‘Casodex’ Early Prostate Cancer Trialists Group. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005;76(1):4-10. Abstract

Home